Mechanisms of Resistance to Antibody-Drug Conjugates.
antibody-drug conjugate
enfortumab vedotin
linker
monoclonal antibodies
payload
sacituzumab govitecan
trastuzumab deruxtecan
trastuzumab emtasine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Jun 2023
02 Jun 2023
Historique:
received:
08
05
2023
revised:
29
05
2023
accepted:
30
05
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
The treatment of cancer patients has dramatically changed over the past decades with the advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and innovative T-cell therapy. Antibody-drug conjugates (ADCs) have also revolutionized the treatment of cancer. Several ADCs have already been approved in hematology and clinical oncology, such as trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG) for the treatment of metastatic breast cancer, and enfortumab vedotin (EV) for the treatment of urothelial carcinoma. The efficacy of ADCs is limited by the emergence of resistance due to different mechanisms, such as antigen-related resistance, failure of internalization, impaired lysosomal function, and other mechanisms. In this review, we summarize the clinical data that contributed to the approval of T-DM1, T-DXd, SG, and EV. We also discuss the different mechanisms of resistance to ADCs, as well as the ways to overcome this resistance, such as bispecific ADCs and the combination of ADCs with immune-checkpoint inhibitors or tyrosine-kinase inhibitors.
Identifiants
pubmed: 37298631
pii: ijms24119674
doi: 10.3390/ijms24119674
pmc: PMC10253543
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Immunoconjugates
0
Ado-Trastuzumab Emtansine
SE2KH7T06F
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Expert Rev Anticancer Ther. 2019 Aug;19(8):673-679
pubmed: 31398063
Lancet Oncol. 2020 Oct;21(10):1283-1295
pubmed: 33002436
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Mol Cancer Res. 2012 Dec;10(12):1597-606
pubmed: 23071104
MAbs. 2021 Jan-Dec;13(1):1974150
pubmed: 34486490
Nat Rev Immunol. 2006 May;6(5):343-57
pubmed: 16622479
Clin Cancer Res. 2015 Jul 15;21(14):3298-306
pubmed: 25840969
Expert Opin Biol Ther. 2021 Jul;21(7):841-847
pubmed: 33605810
Lancet. 2019 Aug 31;394(10200):793-804
pubmed: 31478503
Int J Cancer. 2017 Oct 15;141(8):1682-1689
pubmed: 28677116
Blood. 2009 Sep 24;114(13):2721-9
pubmed: 19633198
PLoS One. 2013 Jun 26;8(6):e66961
pubmed: 23840564
Mol Cancer Ther. 2015 Apr;14(4):952-63
pubmed: 25646013
Science. 1993 Jul 9;261(5118):212-5
pubmed: 8327892
Mol Cancer Ther. 2017 Apr;16(4):681-693
pubmed: 28108597
Breast Cancer Res. 2017 Oct 3;19(1):110
pubmed: 28974266
J Med Chem. 2014 Aug 28;57(16):6949-64
pubmed: 24967516
Cancer Res. 1991 Aug 15;51(16):4187-91
pubmed: 1651156
Bioconjug Chem. 2020 Jan 15;31(1):93-103
pubmed: 31747250
Regul Toxicol Pharmacol. 2015 Apr;71(3):444-52
pubmed: 25661711
Breast Cancer Res Treat. 2011 Jul;128(2):347-56
pubmed: 20730488
Blood. 2004 Jun 1;103(11):4276-84
pubmed: 14962898
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
pubmed: 17440164
J Cell Biol. 2016 Jul 4;214(1):25-34
pubmed: 27377248
Ther Adv Urol. 2020 Dec 27;12:1756287220980192
pubmed: 33447264
Leuk Res. 2006 Jul;30(7):777-83
pubmed: 16730060
Chem Pharm Bull (Tokyo). 2019;67(3):173-185
pubmed: 30827997
Mol Cancer Ther. 2014 Jun;13(6):1537-48
pubmed: 24714131
Ann Ist Super Sanita. 2013;49(2):150-68
pubmed: 23771260
Cancer Sci. 2016 Jul;107(7):1039-46
pubmed: 27166974
Ann Oncol. 2016 Dec;27(12):2168-2172
pubmed: 27733376
Signal Transduct Target Ther. 2022 Mar 22;7(1):93
pubmed: 35318309
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108
pubmed: 27026201
Cancer Cell. 2007 Oct;12(4):395-402
pubmed: 17936563
Cancer Cell. 2016 Jan 11;29(1):117-29
pubmed: 26766593
Ann Oncol. 2016 Apr;27(4):619-24
pubmed: 26598545
Mol Pharm. 2019 Sep 3;16(9):3926-3937
pubmed: 31287952
NPJ Breast Cancer. 2023 Apr 18;9(1):28
pubmed: 37072437
Mol Cancer Ther. 2018 Jan;17(1):243-253
pubmed: 29054985
Cancers (Basel). 2023 Feb 17;15(4):
pubmed: 36831621
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729
Cancer Res. 2017 Sep 1;77(17):4639-4651
pubmed: 28687619
Mol Cancer Ther. 2015 Jul;14(7):1605-13
pubmed: 25904506
Cancer Discov. 2021 Oct;11(10):2436-2445
pubmed: 34404686
J Hematol Oncol. 2021 Jan 28;14(1):20
pubmed: 33509252
Clin Cancer Res. 2021 Feb 15;27(4):922-927
pubmed: 32962979
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
Cancer Res. 1995 Dec 1;55(23 Suppl):5857s-5863s
pubmed: 7493360
N Engl J Med. 2022 Jan 20;386(3):241-251
pubmed: 34534430
Br J Cancer. 2020 Mar;122(5):603-612
pubmed: 31839676
Cancer Res. 2008 Nov 15;68(22):9280-90
pubmed: 19010901
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059433
Clin Cancer Res. 2014 Jan 15;20(2):456-68
pubmed: 24097864
Nat Rev Urol. 2021 Feb;18(2):93-103
pubmed: 33239713
J Clin Oncol. 2022 Oct 10;40(29):3365-3376
pubmed: 36027558
Lancet. 2023 May 27;401(10390):1773-1785
pubmed: 37086745
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Nat Rev Cancer. 2008 Jun;8(6):473-80
pubmed: 18469827
Drug Des Devel Ther. 2017 Aug 02;11:2265-2276
pubmed: 28814834
J Clin Oncol. 2023 Jan 1;41(1):22-31
pubmed: 36041086
Clin Cancer Res. 2004 Oct 15;10(20):7063-70
pubmed: 15501986
Pharm Res. 2015 Nov;32(11):3526-40
pubmed: 25759187
J Clin Oncol. 2021 Aug 1;39(22):2474-2485
pubmed: 33929895
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Cancer Res. 2010 Mar 15;70(6):2528-37
pubmed: 20197459
Clin Cancer Res. 2023 Apr 14;29(8):1496-1505
pubmed: 36534531
Br J Cancer. 2016 Feb 16;114(4):362-7
pubmed: 26742008
Exp Hematol. 1999 Oct;27(10):1533-41
pubmed: 10517495
Cancer Res. 2015 Dec 15;75(24):5329-40
pubmed: 26631267
Clin Cancer Res. 2016 Aug 1;22(15):3755-63
pubmed: 26920887
Bioconjug Chem. 2015 May 20;26(5):919-31
pubmed: 25915780
Oncoimmunology. 2017 Nov 20;7(3):e1395127
pubmed: 29375935
Int J Mol Sci. 2016 Apr 14;17(4):561
pubmed: 27089329
Pharm Res. 2015 Nov;32(11):3494-507
pubmed: 25585957
J Hematol Oncol. 2023 Jan 17;16(1):3
pubmed: 36650546
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Cancer Discov. 2021 Oct;11(10):2474-2487
pubmed: 33941592
Oncotarget. 2015 Sep 8;6(26):22496-512
pubmed: 26101915
Cancer Res. 2016 May 15;76(10):3003-13
pubmed: 27013195
Nat Rev Clin Oncol. 2021 Jun;18(6):327-344
pubmed: 33558752
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Cancer Res. 2006 Apr 15;66(8):4426-33
pubmed: 16618769
Cancer Res. 2016 May 1;76(9):2710-9
pubmed: 26921341
Bioconjug Chem. 2017 May 17;28(5):1371-1381
pubmed: 28388844
Cancer Res. 2005 Jan 15;65(2):473-82
pubmed: 15695389
Breast Cancer Res. 2014 Mar 05;16(2):209
pubmed: 24887180
Cancer Treat Rev. 1978 Dec;5(4):199-207
pubmed: 367597
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
Nature. 1975 Jun 5;255(5508):487-8
pubmed: 1138199
Biochem Pharmacol. 2016 Feb 15;102:1-6
pubmed: 26686577
J Clin Oncol. 2009 Dec 1;27(34):5838-47
pubmed: 19884552
Oncologist. 2003;8(5):411-24
pubmed: 14530494
Clin Cancer Res. 2017 Nov 15;23(22):7006-7019
pubmed: 28821558
Cancer Cell Int. 2022 Aug 13;22(1):255
pubmed: 35964048
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
Cancer Metastasis Rev. 2013 Jun;32(1-2):211-27
pubmed: 23093326